CJC-1295 + Ipamorelin + GHRP-2 / GHRP-6
Triple-stack adding an older, stronger secretagogue
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
The three-component combination has never been studied. There is no trial, no case series, and no animal work testing CJC-1295 with ipamorelin and a GHRP together, so every claim about the stack's superiority over the two-peptide version is inference rather than measurement. What exists is component evidence, and it is uneven. GHRP-2 has the most human data because it was developed as a diagnostic agent and tested for its ability to provoke a growth-hormone pulse, which it reliably does. GHRP-6 has decades of pharmacological characterization and was instrumental in the discovery of ghrelin, but almost no controlled outcome data in healthy adults. Ipamorelin failed to show benefit in its one serious clinical program. CJC-1295 has small early-phase human pharmacokinetic and hormone-response data showing sustained elevation of growth hormone and IGF-1. Crucially, raising growth hormone is a laboratory result, not a clinical outcome. No study of any of these compounds demonstrates durable muscle gain, fat loss, or improved recovery in healthy people, and combining agonists that act on the same ghrelin receptor may produce redundancy rather than addition.
- FDA
- No component is FDA-approved for any use. GHRP-2 and GHRP-6 are also on the FDA's list of peptides that cannot be legally compounded. Available only through unregulated channels.
- WADA
- Prohibited
Reference only. Not medical advice.
What can go wrong
This variant carries all the risks of the base stack plus more, because GHRP-2 and GHRP-6 are stronger and less selective. GHRP-6 in particular causes pronounced hunger and can raise cortisol (a stress hormone) and prolactin (a hormone that, when elevated, can cause breast tenderness or fluid changes). The shared GH risks remain: dose-dependent insulin resistance and higher blood sugar, fluid retention, joint pain, tingling or carpal-tunnel symptoms, and the theoretical concern that raising insulin-like growth factor 1 (IGF-1) could accelerate existing or hidden tumors, so people with cancer history are generally advised to avoid these. Stacking three GH-raising agents amplifies the size and unpredictability of the GH response. Nothing here is FDA-approved, all are prohibited for athletes, and sourcing is unregulated.
Talk to a clinician before taking this, particularly if you have any history of cancer. The Atlas can tell you what has been studied about CJC-1295 + Ipamorelin + GHRP-2 / GHRP-6. It cannot tell you how it would interact with your body, your history, or anything else you are taking, and nothing on this page is a reason to start.
This is the basic CJC-1295 plus Ipamorelin pairing with an older, more potent growth-hormone secretagogue added: GHRP-2 or GHRP-6. GHRP stands for growth-hormone-releasing peptide; these are compounds that mimic ghrelin (the hunger hormone) to trigger a strong pulse of growth hormone (GH). GHRP-6 is the original of its class and is known for sharply increasing appetite; GHRP-2 is a related, slightly more selective version that also raises appetite. The reasoning behind the triple-stack is to combine a long-acting GHRH analog (CJC-1295), a clean secretagogue (Ipamorelin), and a stronger secretagogue (a GHRP) for a larger overall GH release. None of these are FDA-approved, and the three-way combination has never been formally tested in people. It is mainly used in the bodybuilding community and by aggressive optimization clinics; the trade-off is usually more side effects such as intense hunger, water retention, and cortisol or prolactin effects (especially with GHRP-6). As with all of these, purity and dosing from unregulated sources are not guaranteed.
aggressive GH triple-stack
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
Safety in detail
Nothing in this combination is approved anywhere as a treatment. GHRP-2 holds a narrow Japanese approval as a pituitary diagnostic agent, which is often misrepresented by sellers as general approval. In the United States, GHRP-2, GHRP-6, ipamorelin, and CJC-1295 all sit in the FDA's category of bulk substances judged to pose significant safety risks in compounding, which removed the compounding-pharmacy route that many clinics previously used. All three secretagogue classes fall under the World Anti-Doping Agency's prohibited growth-hormone-releasing factors, banned at all times. Material reaching users is research-grade and unregulated, so identity, purity, endotoxin load, and actual peptide content vary widely between vendors. What is genuinely unknown is whether stacking two ghrelin-receptor agonists on top of a GHRH analog produces meaningful added benefit or simply added cortisol, prolactin, and glucose disturbance.
What people get wrong
Often saidMyth: Adding a stronger secretagogue just means better results.
ActuallyReality: It mainly adds side effects (hunger, cortisol and prolactin effects from GHRP-6) with no human data on the three-way combination.
Often saidMyth: These are tested protocols.
ActuallyReality: The triple-stack has no human trials; its rationale is extrapolated from single-compound studies and gym experience.
Who profits, and who pushes back
U.S. Food and Drug Administration
Classifies GHRP-2 and GHRP-6 among peptides that are unapproved and cannot be lawfully compounded.
Endocrinologists (general)
Note that adding a GHRP raises cortisol and prolactin and amplifies insulin-resistance and fluid-retention risks with no proven added benefit.
World Anti-Doping Agency
Lists all GHRPs and GH secretagogues as Prohibited at all times.
Bodybuilding / performance community
Decades of GHRP use; favors maximal GH response.
Aggressive optimization clinics
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Tiered offerings increase per-patient revenue.
Online peptide vendors
Sells this. Has a commercial interest in a product sold as this compound, as of July 2026.
Marketed without medical oversight in many cases.
Where the research comes from
Most of the published research on this comes from one place. 50% of it is from North America. Findings that no unrelated group has reproduced are weaker than the study count makes them look.
| Place | Share of published research |
|---|---|
| North America | 50% |
| Asia-Pacific | 20% |
| Europe | 18% |
| Latin America | 7% |
| Other | 5% |
Research published from: United States.
How we got here
Each piece of this stack has a separate paper trail. GHRP-6 came out of Cyril Bowers's laboratory work at Tulane University, which grew from earlier observations that certain opioid peptide analogs released growth hormone through a receptor entirely distinct from the GHRH receptor. GHRP-2, known pharmacologically as pralmorelin, was developed in collaboration with Japanese chemistry groups and went furthest of the three toward legitimacy, reaching approval in Japan as a single-dose diagnostic agent for testing pituitary growth-hormone reserve rather than as a treatment. Ipamorelin was described by researchers at Novo Nordisk in the late 1990s and was later pursued in clinical trials for postoperative ileus, a use unrelated to bodybuilding, which did not survive mid-stage testing. CJC-1295 originated at ConjuChem in Montreal, where a drug-affinity-complex linker was attached to a modified GHRH fragment so it would bind albumin and circulate for days. Nobody assembled these three into a protocol in a laboratory. The triple-stack is a message-board construction that spread through bodybuilding forums in the late 2000s, was repackaged by peptide vendors as premixed blends, and then migrated into anti-aging and optimization clinics. No named originator, patent, or published protocol covers the combination.
The growth-hormone-releasing-peptide class traces to work by Cyril Bowers and colleagues in the 1980s; GHRP-6 was the founding compound and its receptor work helped lead to the discovery of ghrelin in 1999. GHRP-2 followed as a related analog. These predate Ipamorelin and CJC-1295. Layering all three is a community and clinic practice that arose in bodybuilding circles; no formal protocol, patent, or named originator exists for the triple-stack, so any originator claim is unvalidated.
- 1980sBowers and colleagues develop the first GHRPs, including GHRP-6
- 1990sGHRP-2 characterized as a related secretagogue
- 1999Ghrelin discovered, explaining how GHRPs work
- 2010sTriple-stacks circulate in bodybuilding and clinic protocols
- 2024FDA confirms GHRP-2/GHRP-6 are unapproved and not compoundable
At a glance
- FDA-approved?
- No component approved
- WADA status
- Prohibited (all GHRPs listed)
- GHRP-6 known effect
- Strong hunger stimulation
- Triple-stack trials
- None
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about CJC-1295 + Ipamorelin + GHRP-2 / GHRP-6. A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
GHRP-2, GHRP-6, ipamorelin, and CJC-1295 were evaluated by the FDA as bulk drug substances for compounding and placed in the category judged to present significant safety risks.
Growth hormone releasing factors and their secretagogues, including GHRP-2, GHRP-6, ipamorelin, and CJC-1295, are prohibited at all times in sport under section S2 of the Prohibited List.
Receptor work originating with the GHRP class led to the identification of ghrelin as the endogenous growth-hormone-releasing acylated peptide from stomach.
Ipamorelin was characterized as a selective growth-hormone-releasing peptide with minimal effect on ACTH and cortisol, distinguishing it from GHRP-2 and GHRP-6.
European Journal of Endocrinology (Raun et al., 1998)
CJC-1295 produced sustained elevation of growth hormone and IGF-1 in early-phase human dosing studies conducted by its developer.
Journal of Clinical Endocrinology and Metabolism (Teichman et al., 2006)
The growth-hormone-releasing peptide class was developed and pharmacologically characterized by Cyril Bowers and colleagues beginning in the 1980s.
Endocrine and pituitary review literature (Bowers)
GHRP-2, under the name pralmorelin, was approved in Japan for use as a diagnostic agent for growth hormone deficiency rather than as a therapeutic.
Kaken Pharmaceutical / Japanese regulatory listing
No registered trial exists testing CJC-1295, ipamorelin, and a GHRP administered together as a combination.
Anti-doping authorities warn that peptide products sold to athletes are unregulated, frequently mislabeled, and carry sanction risk regardless of purity.